Zobrazeno 1 - 10
of 77
pro vyhledávání: '"Serena Desideri"'
Autor:
John B Fiveash, Xiaobu Ye, David M Peerboom, Tom Mikkelsen, Sajeel Chowdhary, Myrna Rosenfeld, Glenn J Lesser, Joy Fisher, Serena Desideri, Stuart Grossman, Lance Leopold, Louis B Nabors
Publikováno v:
PLoS ONE, Vol 19, Iss 1, p e0291128 (2024)
PurposeAT-101 is an oral bcl-2 family protein inhibitor (Bcl-2, Bcl-XL, Mcl-1, Bcl-W) and potent inducer of proapoptotic proteins. A prior study of the parent compound, racemic gossypol, demonstrated objective and durable responses in patients with m
Externí odkaz:
https://doaj.org/article/3a7282a455c641f994b16aeb5f9d2b23
Autor:
Xiaobu Ye, Serena Desideri, Ignacio Garcia Ribas, April Eichler, L. Burt Nabors, Manmeet S. Ahluwalia, Myrna R. Rosenfeld, Tom Mikkelsen, Andrew S. Chi, Stuart A. Grossman, Jaishri O. Blakeley
Supplementary Table 1 from Phase II Study of Iniparib with Concurrent Chemoradiation in Patients with Newly Diagnosed Glioblastoma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2cd16a011855237989e70b221e8a139f
https://doi.org/10.1158/1078-0432.22473791
https://doi.org/10.1158/1078-0432.22473791
Autor:
Xiaobu Ye, Serena Desideri, Ignacio Garcia Ribas, April Eichler, L. Burt Nabors, Manmeet S. Ahluwalia, Myrna R. Rosenfeld, Tom Mikkelsen, Andrew S. Chi, Stuart A. Grossman, Jaishri O. Blakeley
Purpose:Iniparib is a purported prodrug causing cell death through intracellular conversion to nitro radical ions. We assessed the efficacy and safety of iniparib with standard radiotherapy and temozolomide in patients with newly diagnosed glioblasto
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4fe74e8c0343ff636c1fd2e0e9eced66
https://doi.org/10.1158/1078-0432.c.6528608.v1
https://doi.org/10.1158/1078-0432.c.6528608.v1
Autor:
Patrick Y. Wen, Michael D. Prados, Igor Espinoza-Delgado, Matthew M. Ames, Xiabu Ye, Serena Desideri, Jihong Xu, Renee M. McGovern, Andrew B. Lassman, Frank S. Lieberman, H. Ian Robins, Mark R. Gilbert, W. K. Alfred Yung, Jan Drappatz, Susan M. Chang, Timothy F. Cloughesy, Kathleen R. Lamborn, John G. Kuhn, Joel M. Reid, Vinay K. Puduvalli, Eudocia Q. Lee
PDF file, 80K, Supplementary Table 1: Temozolomide 150 mg/m2 Pharmacokinetic Parameters (first cycle).
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3218e25e18e7b4e6d8b65f1c7e87c4cd
https://doi.org/10.1158/1078-0432.22447476.v1
https://doi.org/10.1158/1078-0432.22447476.v1
Autor:
Patrick Y. Wen, Michael D. Prados, Igor Espinoza-Delgado, Matthew M. Ames, Xiabu Ye, Serena Desideri, Jihong Xu, Renee M. McGovern, Andrew B. Lassman, Frank S. Lieberman, H. Ian Robins, Mark R. Gilbert, W. K. Alfred Yung, Jan Drappatz, Susan M. Chang, Timothy F. Cloughesy, Kathleen R. Lamborn, John G. Kuhn, Joel M. Reid, Vinay K. Puduvalli, Eudocia Q. Lee
PDF file, 62K, Supplementary Table 2: Grade 3 or 4 events with relationship unrelated to unlikely to combination therapy (Vorinostat + TMZ).
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3824c55e0724a5d0922ef42ae4b6c095
https://doi.org/10.1158/1078-0432.22447473.v1
https://doi.org/10.1158/1078-0432.22447473.v1
Autor:
Patrick Y. Wen, Michael D. Prados, Igor Espinoza-Delgado, Matthew M. Ames, Xiabu Ye, Serena Desideri, Jihong Xu, Renee M. McGovern, Andrew B. Lassman, Frank S. Lieberman, H. Ian Robins, Mark R. Gilbert, W. K. Alfred Yung, Jan Drappatz, Susan M. Chang, Timothy F. Cloughesy, Kathleen R. Lamborn, John G. Kuhn, Joel M. Reid, Vinay K. Puduvalli, Eudocia Q. Lee
Purpose: A phase I, dose-finding study of vorinostat in combination with temozolomide (TMZ) was conducted to determine the maximum tolerated dose (MTD), safety, and pharmacokinetics in patients with high-grade glioma (HGG).Experimental Design: This p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::579e17f33f6813c56b74956393739952
https://doi.org/10.1158/1078-0432.c.6521082
https://doi.org/10.1158/1078-0432.c.6521082
Autor:
Patrick Wen, Caroline Duault, Edgar Gonzalez-Kozlova, Kevin Brennan, Tyson Holmes, Seunghee Kim-Schulze, Kai Nie, Kimberly Argueta, Jacques Fehr, Mina Pichavant, Diane Del Valle, Andrew Gentles, Sacha Gnjatic, Holden Maecker, Xiaobu Ye, David Reardon, Wenya Linda Bi, Pierpaolo Peruzzi, Nirav Patel, Roy Strowd, Stephen Tatter, Ian Lee, Tobias Walbert, James Snyder, Steven Brem, Arati Desai, Stephen Bagley, Nduka Amankulor, Frank Lieberman, Megan Mantica, Lenika Lopez, Susan Bell, Andrea Manzanera, Sean Lawler, Lixian Jin, Neeraja Danda, Serena Desideri, L Burt Nabors, Stuart Grossman, E Chiocca, Paul Tak, Francesca Barone
Publikováno v:
Late-Breaking Abstracts.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::aeab66abcbc189d92953a16f29859e54
https://doi.org/10.1136/jitc-2022-sitc2022.1477
https://doi.org/10.1136/jitc-2022-sitc2022.1477
Autor:
Eudocia Lee, Michelle Rudek, Veronica Rendo, Nicholas Khuu, Tobias Walbert, Matthias Holdhoff, Frank Lieberman, Arati Desai, Roy Strowd, Emily Lapinskas, Kristine Pelton, William Pisano, Serena Desideri, Neeraja Danda, Joy Fisher, Xiaobu Ye, L Burt Nabors, Stuart Grossman, Rameen Beroukhim, Brian Alexander, Keith Ligon, Patrick Y Wen
Publikováno v:
Neuro-Oncology. 24:vii76-vii76
BACKGROUND KRT232 is an orally bioavailable, selective small molecule inhibitor of MDM2 that blocks the protein-protein interaction between MDM2 and p53. We performed a surgical window of opportunity trial of KRT232 in patients with recurrent GBM. ME
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::590c64c3a6e44b524b3572d6a578a708
https://doi.org/10.1093/neuonc/noac209.291
https://doi.org/10.1093/neuonc/noac209.291
Autor:
Karisa Schreck, Roy Strowd, L Burt Nabors, Ben Ellingson, Joy Fisher, Serena Desideri, Neeraja Danda, Michelle Rudek, Stuart Grossman, Xiaobu Ye
Publikováno v:
Neuro-Oncology. 24:vii86-vii86
BACKGROUND Although < 5% of high-grade gliomas (HGG) are BRAF-V600E mutated, these tumors are being identified more frequently as genetic testing increases in gliomas. Given the treatment-refractory nature HGG, RAF-targeted therapy is of special inte
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::55f49c24fdb79e30c7d89ad8d3a46033
https://doi.org/10.1093/neuonc/noac209.325
https://doi.org/10.1093/neuonc/noac209.325
Autor:
Carlos Romo, Benjamin Ellingson, Roy Strowd, Glenn Lesser, Catalina Raymond, Brian Kral, Xiaobu Ye, Serena Desideri, Joy Fisher, Stuart Grossman
Publikováno v:
Neuro-Oncology. 24:vii96-vii96
BACKGROUND The blood brain barrier (BBB) is a major obstacle to the delivery of chemotherapy to the CNS. Regadenoson is an FDA approved adenosine A2 agonist used for cardiac stress tests. In murine models, it transiently increases BBB permeability to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f088d9a8b59d9e41335de29124dea6a4
https://doi.org/10.1093/neuonc/noac209.357
https://doi.org/10.1093/neuonc/noac209.357